FDA：谨慎使用氟奎喏酮类药治疗某些感染
美国食品与药物管理局(FDA)于近期发布较强警告信息，氟奎喏酮类药物用于鼻窦感染、泌尿道感染和支气管炎时，可能使既往存在的慢性阻塞性肺疾病复杂化。
美国食品与药物管理局(FDA)于近期发布较强警告信息，氟奎喏酮类药物用于鼻窦感染、泌尿道感染和支气管炎时，可能使既往存在的慢性阻塞性肺疾病复杂化。
与抗生素相关的安全警示还包括心律失常、周围神经病变和认知问题。报告显示，一些患者可能出现永久性的副作用。
FDA Advisers Recommend Stronger Warnings on Fluoroquinolones
By Amy Orciari Herman
Edited bySusan Sadoughi, MD, andAndré Sofair, MD, MPH
An FDA advisory panel voted late last week to recommend stronger label warnings on fluoroquinolones (e.g., ciprofloxacin) when used to treat sinus infections, urinary tract infections, and bronchitis that complicates preexisting chronic obstructive pulmonary disease, theWall Street Journalreports.
Safety concerns include increasing reports of cardiac rhythm disturbances, peripheral neuropathy, and cognitive problems associated with the antibiotics. Some patients have reported permanent side effects.
The panel voted 21-0 to update the warnings for sinusitis treatment, 18-2 (1 abstention) for bronchitis, and 20-1 for urinary tract infections. The FDA usually follows its advisers' advice, although it is not required to do so.
Asked to comment, infectious disease expert Dr. Paul Sax said: "While fluoroquinolones are usually safe, there is an increasing appreciation that rarely they may cause severe and sometimes permanent side effects. The additional warnings will be a reminder that no antibiotic should be used unless clearly indicated."
相关文章
评论
我要跟帖
